Analyst consensus for Spectral AI's second quarter points to revenue of $8.50 million and an EPS of -$0.14, while the stock currently trades significantly below the $6.00 average analyst price target.
Investors are primarily focused on the progress of the commercial rollout and clinical adoption of the DeepView System for burn wound assessment. The company continues to transition from government-funded R&D revenue toward commercial healthcare market penetration. Management's commentary regarding the timeline for the Diabetic Foot Ulcer (DFU) clinical study results will also be a critical factor for near-term valuation.